NeuroMetrix, Inc. Announces Date for 2012 Second Quarter Financial Results Conference Call
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 18, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012
second quarter financial results before the opening of the market on
July 26, 2012. The Company will host a conference call at
8:00 a.m.,
Eastern Time on
July 26, 2012 to discuss its second quarter financial
results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing
866-813-5647 and using the confirmation code 32913623. Internationally,
the conference call may be accessed by dialing 847-619-6249 and using
the same confirmation code. The earnings press release and accompanying
condensed financial statements will be accessible from the Company's
website at www.neurometrix.com
under the "Investors" tab.
A replay of the conference call will be available starting two hours
after the call by dialing 888-843-7419, domestically and 630-652-3042,
internationally. The confirmation code to access the replay is 32913623.
The replay will be available for three months after the conference call.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device. The company
has additional therapeutic products in its pipeline. For more
information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
